RBC Capital Upgrades Repligen (RGEN) to Outperform, 'Getting Off the Bioproduction Bench'
Tweet Send to a Friend
RBC Capital analyst Conor McNamara upgraded Repligen (NASDAQ: RGEN) from Sector Perform to Outperform with a price target of $157.00.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
